Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has issued an announcement.
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for the change of marketing license holder for its Eszolam tablets. This approval follows a contract signed with Guangxi Dahai Sunshine Pharmaceutical Company Limited for the transfer of the Marketing Authorization Holder status and related technical ownership rights, marking a significant step in the company’s strategic operations.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, focusing on the production and marketing of prescription drugs. The company is involved in the development and commercialization of various pharmaceutical products, with a particular emphasis on prescription medications.
YTD Price Performance: -7.75%
Average Trading Volume: 2,131,863
Technical Sentiment Signal: Hold
Current Market Cap: HK$8.24B
For an in-depth examination of 0719 stock, go to TipRanks’ Stock Analysis page.